Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Alto Neuroscience, Inc. (ANRO : NYSE)

• Company Description    Alto Neuroscience Inc. is a clinical-stage biopharmaceutical company. Its clinical-stage pipeline includes novel drug candidates in depression, PTSD, schizophrenia and other mental health conditions. Alto Neuroscience Inc. is based in LOS ALTOS, Calif. Number of Employees: 68

• Price / Volume Information    Yesterday's Closing Price: $21.22 Daily Weekly Monthly 20 Day Moving Average: 313,940 shares Shares Outstanding: 35.09 (millions) Market Capitalization: $744.69 (millions) Beta: 1.62 52 Week High: $28.44 52 Week Low: $2.15 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -17.46% -21.50% 12 Week 10.01% 1.69% Year To Date 19.21% 11.26%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 650 CASTRO STREET SUITE 450 - MOUNTAIN VIEW,CA 94041 USA ph: 650-200-0412 fax: - investors@altoneuroscience.com http://www.altoneuroscience.com

• General Corporate Information    Officers Amit Etkin - Chief Executive Officer; Chairman and President Nicholas Smith - Chief Financial Officer Christopher Nixon Cox - Director Andrew Dreyfus - Director Husseini Manji - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 02157Q109 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/12/26 Share - Related Items Shares Outstanding: 35.09 Most Recent Split Date: (:1) Beta: 1.62 Market Capitalization: $744.69 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.74 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.86 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/12/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.06 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -50.94% vs. Previous Quarter: -77.78% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - -47.22 12/31/25 - -47.64 09/30/25 - -46.87 ROA 03/31/26 - -38.81 12/31/25 - -37.83 09/30/25 - -37.64 Current Ratio 03/31/26 - 20.52 12/31/25 - 15.69 09/30/25 - 15.42 Quick Ratio 03/31/26 - 20.52 12/31/25 - 15.69 09/30/25 - 15.42 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - 6.93 12/31/25 - 4.87 09/30/25 - 4.12 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.07 12/31/25 - 0.12 09/30/25 - 0.20 Debt-to-Capital 03/31/26 - 6.25 12/31/25 - 10.85 09/30/25 - 16.75

Powered by Zacks Investment Research ©